Company: Carolina Longevity Institute LLC (CLI)
Job title: Chief Operations and Scientific Officer
Brian Huber is currently Chief Operations and Scientific Officer at the Carolina Longevity Institute LLC (CLI), Research Triangle Park, NC. CLI is an emerging portfolio of companies on a mission to enable people to live longer and to age healthier with better quality of life through innovative clinical research and world class clinics that offer the most advanced and proven treatments that promote healthy aging. With more than 35 years of experience and demonstrated success in the biopharmaceutical drug development and investment sectors, Brian Huber leads the scientific, clinical, and operational activities at CLI.
Preceding his position at CLI, Huber worked for 10 years as Managing Director and VP of Drug Development Partnerships at Quintiles/IQVIA. His prior experience over the course of 25 years was as Global VP in Drug Discovery at GlaxoSmithKline (GSK) and Senior Staff Fellow / Section Head at the National Cancer Institute of the National Institutes of Health. Huber’s experience has ranged from basic cancer/ antiviral research, managing drug discovery and clinical drug development portfolios, managing key partnerships, to identifying, structuring, and managing innovative clinical investments involving biopharmaceutical companies.
Huber holds a Ph.D. in pharmacology from The George Washington University and a B.S. and M.S. from Villanova University. He is Board Certified in Clinical Pharmacology and has completed residency programs in Advanced Leadership from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill and at the London Business School.He holds adjunct academic positions at Duke University and The George Washington University and has over 60 peer reviewed publications and multiple patents.
Clinical Evaluation & Regulatory Considerations in the Approval of Biopharmaceuticals for Health-Span Indications 4:15 pm
Discussing how the clinical development strategy and regulatory approval pathway for health-span and longevity related biopharmaceutical drugs is still evolving and being established Exploring lessons learned from other examples where the clinical indication needed to be established and the approval pathway created Drawing parallels and hypothesizing pathwaysRead more
day: Day Two